Impaired flow-mediated vasodilatation and insulin resistance in type 2 diabetic patients with albuminuria

Diabetes Research and Clinical Practice

Volumn 79, Issue 1, 2008, Pages 177-182

  Makino, Hisashi ^a   Doi, Kentaro ^a   Hiuge, Aki ^a   Nagumo, Ayako ^a   Okada, Sadanori ^a   Miyamoto, Yoshihiro ^a   Suzuki, Masaaki ^a   Yoshimasa, Yasunao ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Atherosclerosis; Diabetic nephropathy; Endothelial dysfunction; Nitric oxide

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; GLUCOSE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; VON WILLEBRAND FACTOR;

ADULT; AGED; ALBUMINURIA; ARTICLE; ATHEROSCLEROSIS; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; RISK FACTOR; STEADY STATE; URINARY EXCRETION; VASCULAR ENDOTHELIUM; VASODILATATION;

AGED; ALBUMINURIA; BLOOD FLOW VELOCITY; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CREATININE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; VASODILATION; VON WILLEBRAND FACTOR;

EID: 37549068092     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.08.014     Document Type: Article

References (28)

1. Dinneen S.F., and Gerstein H.C. The association of microalbuminuria and mortality in non-insulin dependent diabetes mellitus: a systematic overview of the literature. Arch. Intern. Med. 157 (1997) 1413-1418
2. Yudkin J.S., Forrest R.D., and Jackson C.A. Microalbuminuria as predictor of vascular disease in non-diabetic subjects: Islington diabetes survey. Lancet 2 (1988) 530-533
3. Boger R.H., and Ron E.S. l-Arginine improves vascular function by overcoming the deleterious effects of ADMA, a novel cardiovascular risk factor. Altern. Med. Rev. 10 (2005) 14-23
4. Fleming I., and Busse R. Significant transduction of eNOS activation. Cardiovasc. Res. 43 (1999) 532-541
5. Busse R., and Fleming I. Pulsatile stretch and shear stress: physical stimuli determining the production of endothelium-derived relaxing factors. J. Vasc. Res. 35 (1998) 73-84
6. Celemajer D.S., Sorensen K.E., Gooch V.M., Spiegelhalter D.J., Miller O.I., Sullivan I.D., et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340 (1992) 1111-1115
7. Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
8. De Fronzo R.A., and Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 14 (1991) 173-194
9. Inchiostro S., Bertoli G., and Zanette G. Evidence of higher insulin resistance in NIDDM patients with ischemic heart disease. Diabetologia 37 (1994) 597-603
10. Emoto M., Nishizawa Y., Maekawa K., Kawagishi T., Kogawa K., Hiura Y., et al. Insulin resistance in non-insulin-dependent diabetic patients with diabetic nephropathy. Metabolism 46 (1997) 1013-1018
11. Suzuki M., Takamizawa I., Suzuki K., Hiuge A., Horio T., Yoshimasa Y., et al. Close association of endothelial dysfunction with insulin resistance and carotid wall thickening in hypertension. Am. J. Hypertens. 17 (2004) 228-232
12. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
13. Ihlemann N., Stokholm K.H., and Eskildsent P.C. Impaired vascular reactivity is present despite normal levels of von Willebrand factor in patients with uncomplicated type 2 diabetes. Diabetes Med. 19 (2002) 476-481
14. Hogikyan R.V., Galecki A.T., Pitt B., Halter J.B., Greene D.A., and Supiano M.A. Specific impairment of endothelium-dependent vasodilatation in subjects with type 2 diabetes independent of obesity. J. Clin. Endocrinol. Metab. 83 (1998) 1946-1952
15. Ewenstein B.M. Vascular biology of von Willebrand factor. In: Born G.V.R., and Schwartz C.J. (Eds). Vascular Endothelium (1997), Schattauer, Stuttgart 107-123
16. Gschwend S., Pinto-Siersma S.J., Buikema H., Pinto Y.M., Van Gilst W.H., Schulz A., et al. Impaired coronary endothelial function in a rat model of spontaneous albuminuria. Kidney Int. 62 (2002) 181-191
17. Erdely A., Freshour G., Maddox D.A., Olson J.L., Samsell L., and Baylis C. Renal disease in rats with type 2 diabetes is associated with decreased renal nitric oxide production. Diabetologia 47 (2004) 1672-1676
18. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339 (1992) 572-575
19. Torzewski J., Torzewski M., Bowyer D.E., Frohlich M., Koenig W., Waltenberger J., et al. C-reactive protein frequently colocalizes with the terminal component complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1386-1392
20. Ridker P.M., Cushman M., Stampfer M.J., Tracy R., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336 (1997) 973-979
21. Haverkate F., Thompson S.G., Pyke S.D.M., Gallimore J.R., Pepys M.B., and The European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 349 (1997) 462-466
22. Ford E.S. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 22 (1999) 1971-1977
23. Stehouwer C.D.A., Gall M.A., Twisk J.W.R., Knudsen E., Emeis J.J., and Parving H.H. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes. Progressive, interrelated, and independently associated with risk of death. Diabetes 51 (2002) 1157-1165
24. Paisley K.E., Beaman M., Tooke J.E., Mohamed-Ali V., Lowe G.D.O., and Shore A.C. Endothelial dysfunction and inflammation in asymptomatic proteinuria. Kidney Int. 63 (2003) 624-633
25. Mirup B., Demaat M., Rossing P., Gram J., Kluft C., and Jespersen J. Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. Thromb. Res. 81 (1996) 485-490
26. Crook M.A., Tutt P., and Pickup J.C. Elevated serum sialic acid concentration in NIDDM and its relationship to blood pressure and retinopathy. Diabetes Care 16 (1993) 57-60
27. Ortega O., Rodriguez I., Gallar P., Carreno A., Ortiz M., Molina A., et al. Significance of high C-reactive protein levels in pre-dialysis patients. Nephrol. Dial. Transplant. 17 (2002) 1105-1109
28. Nakamura T., Ushiyama C., Osada S., Hara M., Shimada N., and Koide H. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 50 (2001) 1193-1196